## **CENTER FOR DRUG EVALUATION AND RESEARCH**

**APPLICATION NUMBER: 020280/S008** 

**CHEMISTRY REVIEW(S)** 

## BEST POSSIBLE COPY

	1. ORGANIZATION	2. NDA NUMBER IIIM 3 N 1997
CHEMISTS REVIEW	DMEDP II, HFD-510	2. NDA NUMBER
3. NAME AND ADDRESS OF APPLICANT		4. SUPPLEMENT NUMBER, DATE
Pharmacia & Upjohn 700 Portage Rd. Kalamazoo, MI 49001-0199		SEI-008 1-11-974 11-1-96
5. PROPRIETARY NAME	6. NAME OF THE DRUG	7. AMENDMENTS, REPORT, DATE
Genotropin	somatropin (rDNA) for injection	
8. SUPPLEMENT PROVIDES FOR		
A new indication for the drug for "long-term replacement threapy in adults with growth-hormone deficiency."		
9. PHARMACOLOGICAL CATEGORY	10. HOW DISPENSED	11. RELATED IND, NDA, DMF
growth hormone	RX	
12. DOSAGE FORM	13. POTENCY	
small volume parenteral	1.3, 5.0, and 12, mg/mL (equivalent to 4, 15, and 36 IU/mL)	
14. CHEMICAL NAME AND STRUCTURE		
See Chemistry Review #1		
15. COMMENTS		
This supplemental application seeks approval for a new indication for Gentoropin to be used to treat adult growth-hormone deficiency. The sponsor has, in addition to the clinical results, provided updated labeling to include the new indication, clinical pharmacology, reviews of the clinical results, a dose and administration section for adult users, and changes to conform to the "pediatric patients" rules. The annotated labeling provided with the application is acceptable. Additionally, the sponsor has provided an abreviated EA to support the application. The EA has been reviewed and found to be adequate		
16. CONCLUSION AND RECOMMENDATION		
The sponsor has provided appropriate labeling to support the proposed indication. No CMC changes were instituted. Updated EA information was provided and is acceptable. The application is approvable from a chemistry standpoint.		
17. NAME	18. REVIEWERS SIGNATURE	19. DATE COMPLETED
WILLIAM K. BERLIN 6-17-97		
DISTRIBUTION: ORIGINAL JACKET	CSO REVIEWER	DIVISION FILE

/\$/ 1 6/30/97